BioSpace News Archive

Ainos, Inc., entered into an exclusive agreement to serve as the master sales and marketing agent for the Ainos SARS-CoV-2 Antigen Rapid Test Kit for Taiwan Carbon Nano Corporation.

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Investigational New Drug (IND) application for the company’s novel Bcl-2 inhibitor, lisaftoclax (APG-2575), has been cleared by the US Food and Drug Administration (FDA)

Labcorp (NYSE: LH), and OmniSeq, a CAP-accredited, molecular diagnostic innovation of Roswell Park Comprehensive Cancer Center, today announced the launch of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling, tissue-based test that integrates next-generation sequencing (NGS) technology.

Today, Aventus Health (Aventus), a comprehensive healthcare company focused on making precision medicine accessible and affordable, announced the availability of their COVID-19 Variant Test, created to reliably identify known SARS-CoV-2 variants and the discovery of novel variants

The report highlights the trends prevalent in the global bone cement market and the factors driving the market along with those that act as deterrents to its growth.

The Global medical equipment maintenance market is expected to reach US$ 36,525.26 Mn in 2027 from US$ 16,943.29 Mn in 2018.

AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Shannon Haymond, PhD, DABCC, FAACC, has been elected to serve on the AACC Board of Directors as president-elect starting in August 2021.

The market is estimated to grow with a CAGR of 7.7% from 2019-2027. The report highlights the trends prevalent in the global transradial access market and the factors driving the market along with those that act as deterrents to its growth.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced the appointment of Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer.

Biogen Inc. (Nasdaq: BIIB) today announced topline results from the Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia.